| 发明名称 | Fc variants with altered binding to FcRn | ||
| 摘要 | The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | ||
| 申请公布号 | US8852586(B2) | 申请公布日期 | 2014.10.07 |
| 申请号 | US201012697933 | 申请日期 | 2010.02.01 |
| 申请人 | Xencor, Inc. | 发明人 | Chamberlain Aaron Keith;Dahiyat Bassil I.;Desjarlais John R.;Karki Sher Bahadur;Lazar Gregory Alan |
| 分类号 | A61K39/395;A61K39/40;C07K16/28;C07K16/42;C07K16/32;C07K16/08;C07K16/24;C07K16/22;C07K16/00;A61K39/00 | 主分类号 | A61K39/395 |
| 代理机构 | Morgan, Lewis & Bockius, LLP | 代理人 | Talukdar Gargi;Silva Robin M.;Morgan, Lewis & Bockius, LLP |
| 主权项 | 1. A method of increasing antibody serum half-life in a patient comprising administering to said patient an antibody comprising a variant Fc region as compared to a parent Fc region, wherein said variant Fc region comprises an isoleucine at position 259 and a phenylalanine at position 308, wherein said antibody has increased in vivo half-life as compared to an antibody comprising said parent Fc region, and wherein numbering is according to the EU index. | ||
| 地址 | Monrovia CA US | ||